glp 1 drugs and gallstones Why are GLP-1 agonists being used to treat patients with nonalcoholic fatty liver disease? Dr. - 🚨 WARNING: Black

Data from numerous clinical trials primarily evaluating the antihyperglycemic effects of multiple GLP-1 RAs have also revealed that changes in most CVD risk markers reported as secondary outcomes have been in favor of GLP-1 RAs treatment

Related Resources Saxenda Side Effects: Common, Serious, & How to Reduce Saxenda side effects

Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes

The work is mainly aimed at boosting efficacy, making patient convenience a bit easier, and pushing therapeutic use beyond diabetes management, like more metabolic needs

Meta-Analyses and Real-World Evidence A 2021 meta-analysis of major CVOTs confirmed a 14% MACE reduction (HR 0.86, 95% CI 0.80-0.93) with GLP-1 agonists, with significant reductions in MI, stroke, cardiovascular death, and all-cause mortality [51]